The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer Policy

Bayer agrees to $7.25B settlement over lawsuits alleging Roundup weedkiller caused cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Bayer, the owner of the herbicide Roundup, offered $7.25 billion to settle thousands of lawsuits alleging that the product is responsible for causing cases of Non-Hodgkin lymphoma. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase inhibitor, plus a two-year venetoclax and rituximab regimen versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001), according to the results of the phase III BRUIN CLL-322 trial. The study met its primary endpoint of independent review committee-assessed progression-free survival.
Clinical Roundup

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results. 
Byline
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account